ADB-BINACA

ADB-BINACA
Legal status
Legal status	CA: Schedule II; DE: Anlage II (Authorized trade only, not prescriptible); UK: Class B; US: Schedule I;
Identifiers
	IUPAC name N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-benzyl-1H-indazole-3-carboxamide;
CAS Number	1185282-27-2 ;
PubChem CID	129406620;
ChemSpider	57621565;
UNII	PUVP61SOSI;
CompTox Dashboard (EPA)	DTXSID501344812 ;
Chemical and physical data
Formula	C21H24N4O2
Molar mass	364.449 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NC(C(N)=O)C(C)(C)C)C1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3;
	InChI InChI=1S/C21H24N4O2/c1-21(2,3)18(19(22)26)23-20(27)17-15-11-7-8-12-16(15)25(24-17)13-14-9-5-4-6-10-14/h4-12,18H,13H2,1-3H3,(H2,22,26)(H,23,27); Key:IUFIUAWRCUVUCQ-UHFFFAOYSA-N;

ADB-BINACA (also known as ADMB-BZINACA using EMCDDA naming standards^[1]) is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products.^[2] It was originally developed by Pfizer as a potential analgesic, and is a potent agonist of the CB₁ receptor with a binding affinity (K_i) of 0.33 nM and an EC₅₀ of 14.7 nM.^[3]

ADB-BUTINACA

The analogue with a 1-butyl substitution on the indazole ring rather than 1-benzyl has also been sold as a designer drug under the name ADB-BINACA, but is now more commonly referred to as ADB-BUTINACA to avoid confusion with the benzyl compound.^[4]^[5]^[6]^[7]^[8] It is a similarly potent CB₁ agonist, with a binding affinity of 0.29nM for CB1 and 0.91nM for CB2, and an EC₅₀ of 6.36 nM for CB1.^[9]^[10]

References

^ Pulver B, Fischmann S, Gallegos A, Christie R (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276. doi:10.1002/dta.3403. PMID 36346325. S2CID 253396419.
^ Qian Z, Hua Z, Liu C, Jia W (2016). "Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances". Forensic Toxicology. 34: 133–143. doi:10.1007/s11419-015-0297-2. PMC 4705129. PMID 26793280.
^ WO 2009106982, "Indazole Derivatives"
^ Kavanagh P, Pechnikov A, Nikolaev I, Dowling G, Kolosova M, Grigoryev A (July 2022). "Detection of ADB-BUTINACA Metabolites in Human Urine, Blood, Kidney and Liver". Journal of Analytical Toxicology. 46 (6): 641–650. doi:10.1093/jat/bkab088. PMID 34341821.
^ Sia CH, Wang Z, Goh EM, Tan YL, Fong CY, Moy HY, et al. (November 2021). "Urinary Metabolite Biomarkers for the Detection of Synthetic Cannabinoid ADB-BUTINACA Abuse". Clinical Chemistry. 67 (11): 1534–1544. doi:10.1093/clinchem/hvab134. PMID 34387654.
^ Kronstrand R, Norman C, Vikingsson S, Biemans A, Valencia Crespo B, Edwards D, et al. (April 2022). "The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB-4en-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons". Drug Testing and Analysis. 14 (4): 634–652. doi:10.1002/dta.3203. PMID 34811926. S2CID 244490343.
^ Wang Y, Pan Y, Yang H, Liu J, Wurita A, Hasegawa K (July 2022). "Quantification of MDMB-4en-PINACA and ADB-BUTINACA in human hair by gas chromatography-tandem mass spectrometry". Forensic Toxicology. 40 (2): 340–348. doi:10.1007/s11419-022-00615-z. PMID 36454410. S2CID 247501663.
^ King A, Hill SL, Pucci M, Bailey G, Keating L, Macfarlane R, et al. (October 2022). "Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England". Clinical Toxicology. 60 (10): 1094–1098. doi:10.1080/15563650.2022.2101469. PMID 35943421. S2CID 251444625.
^ Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, et al. (December 2020). "Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. PMID 33253529. S2CID 227246346.
^ Pike E, Grafinger KE, Cannaert A, Ametovski A, Luo JL, Sparkes E, et al. (July 2021). "Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB₁ receptor activation assays: Part I-Synthesis, analytical characterization, and binding affinity for human CB₁ receptors". Drug Testing and Analysis. 13 (7): 1383–1401. doi:10.1002/dta.3037. PMID 33787091.

[1] Pulver B, Fischmann S, Gallegos A, Christie R (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276. doi:10.1002/dta.3403. PMID 36346325. S2CID 253396419.

[2] Qian Z, Hua Z, Liu C, Jia W (2016). "Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances". Forensic Toxicology. 34: 133–143. doi:10.1007/s11419-015-0297-2. PMC 4705129. PMID 26793280.

[3] WO 2009106982, "Indazole Derivatives"

[4] Kavanagh P, Pechnikov A, Nikolaev I, Dowling G, Kolosova M, Grigoryev A (July 2022). "Detection of ADB-BUTINACA Metabolites in Human Urine, Blood, Kidney and Liver". Journal of Analytical Toxicology. 46 (6): 641–650. doi:10.1093/jat/bkab088. PMID 34341821.

[5] Sia CH, Wang Z, Goh EM, Tan YL, Fong CY, Moy HY, et al. (November 2021). "Urinary Metabolite Biomarkers for the Detection of Synthetic Cannabinoid ADB-BUTINACA Abuse". Clinical Chemistry. 67 (11): 1534–1544. doi:10.1093/clinchem/hvab134. PMID 34387654.

[6] Kronstrand R, Norman C, Vikingsson S, Biemans A, Valencia Crespo B, Edwards D, et al. (April 2022). "The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB-4en-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons". Drug Testing and Analysis. 14 (4): 634–652. doi:10.1002/dta.3203. PMID 34811926. S2CID 244490343.

[7] Wang Y, Pan Y, Yang H, Liu J, Wurita A, Hasegawa K (July 2022). "Quantification of MDMB-4en-PINACA and ADB-BUTINACA in human hair by gas chromatography-tandem mass spectrometry". Forensic Toxicology. 40 (2): 340–348. doi:10.1007/s11419-022-00615-z. PMID 36454410. S2CID 247501663.

[8] King A, Hill SL, Pucci M, Bailey G, Keating L, Macfarlane R, et al. (October 2022). "Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England". Clinical Toxicology. 60 (10): 1094–1098. doi:10.1080/15563650.2022.2101469. PMID 35943421. S2CID 251444625.

[9] Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, et al. (December 2020). "Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. PMID 33253529. S2CID 227246346.

[10] Pike E, Grafinger KE, Cannaert A, Ametovski A, Luo JL, Sparkes E, et al. (July 2021). "Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB₁ receptor activation assays: Part I-Synthesis, analytical characterization, and binding affinity for human CB₁ receptors". Drug Testing and Analysis. 13 (7): 1383–1401. doi:10.1002/dta.3037. PMID 33787091.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

ADB-BUTINACA

See also

References